Salvage chemotherapy with CPT-11 for recurrent meningioma

Journal of Neuro-Oncology

Volumn 78, Issue 3, 2006, Pages 271-276

  Chamberlain, Marc C ^a   Tsao Wei, Denice D ^b   Groshen, Susan ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CPT 11; Meningioma

Indexed keywords

ANTICONVULSIVE AGENT; DEXAMETHASONE; ENZYME INDUCING AGENT; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; MALE; MENINGIOMA; NAUSEA; NEUROLOGIC EXAMINATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; REOPERATION; SALVAGE THERAPY; SEIZURE; STEREOTAXIC SURGERY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT FAILURE; TUMOR RECURRENCE; VOMITING;

AGED; AGRANULOCYTOSIS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 33745792158     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9093-x     Document Type: Article

References (29)

1. Bondy M, Ligon BL, Epidemiology and etiology of intracranial meningiomas. A review J Neuro-Oncol 29:197-205,1996
2. Wilson CB, Meningiomas: Genetics, malignancy, and the role of radiation in induction and treatment J Neurosurg 81:666-675,1994
3. Braunstein JB, Vick NA, Meningiomas: The decision not to operate Neurology 48: 1459-1462, 1997
4. Firsching RP, Fischer A, Peters R, Thun F, Klug N, Growth rate of incidental meningiomas J Neurosurg 73:545-547, 1990
5. Go RS, Taylor BV, Kimmel DW, The natural history of asymptomatic meningiomas in Olmsted County, Minnesota Neurology 51:1718-1720, 1998
6. Goldsmith BJ, Wara WM, Wilson CB, Larson DA, Postoperative irradiation for subtotally resected meningiomas J Neurosurg 80:195-201, 1994
7. Mirimanoff RO, Dosoretz DE, Linggood RM, et al, Meningioma: Analysis of recurrence and progression following neurosurgical resection J Neurosurg 62:18-24, 1985
8. Jaaskelainen J, Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis Surg Neurol 26: 261-469, 1986
9. Kondziolka D, Lunsford D, Coffey RJ, Flickinger JC, Stereotactic radiosurgery of meningiomas J Neurosurg 74:552-559, 1991
10. Lunsford DL, Contemporary management of meningiomas: Radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal? J Neurosurg 80:187-190, 1994
11. Morita A, Coffey RJ, Foote RL, Schiff D, Gorman D, Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: Experience in 88 patients J Neurosurg 90:42-50, 1999.
12. Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD, Gamma knife radiosurgery of image-diagnosed intracranial meningioma Int J Radiat Oncol Biol Phys 56(3): 801-806, 2003
13. Lee JYK, Niranjan A, McInerney J, Kondziolka D, Flickinger JC, Lundsford LD, Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas J Neurosurg 97: 65-72, 2002
14. Kyritisis AP, Chemotherapy for meningiomas J Neuro-Oncol 29: 269-272,1996
15. Grunberg SM, Weiss M, Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma J Neuro-Oncol8:61-65, 1990
16. Grunberg SM, Weis M, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL, Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone J Neurosurg 74:861-866, 1991
17. Lamberts SWJ, Tanghe HLJ, Avezaata CJJ, Braakman R, Wijingaarde R, Koper JW, de Jong FH, Mifepristone (RU-486) treatment of meningiomas J Neurol Neurosurg Psych 55: 486-490, 1992
18. Grunberg SM, Rankin CR, Townsend J, Ahmadi J, Feun L, Fredricks R, Russell C, Kabbinavar F, Barger GR, Seltzer KJ, Phase III double blind randomized placebo-controlled study of mifepristone (RU-486) for the treatment of unresectable meningioma Proceedings ASCO 20: 56a, 2001 (abstract)
19. Wöber-Bringöl Ç, Wöber C, Marosi C, Prayer D, Interferon-alfa-2b for meningioma. Lancet 345: 331, 1995
20. Koper J, Zwarthoff E, Hagemeijer A, Braakman R, Avezaat CJ, Bergstrom M, Lamberts SW: Inhibition of the growth of cultured human meningioma cells by recombinant interferon-a. Eur J Cancer 27: 271-275, 1998
21. Kaba SE, DeMonte F, Bruner JM, et al, The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B Neurosurgery 40(2): 271-275, 1997
22. Schrell UMH, Ritting MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fashlbusch R, Hydroxyurea for treatment of unresectable and recurrent meningiomas J Neurosurg 86:845-852, 1997
23. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey L, Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma J Neurosurg 97: 341-346, 2002
24. Newton HB, Slivka MA, Stevens C, Hydroxyurea chemotherapy for unresectable or residual meningioma J Neuro-Oncol 49(2): 165-170, 2000
25. Chamberlain MC, Malignant meningiomas: Adjunct combined modality therapy J Neurosurg 84: 733-736,1996
26. Chen TC: CPT-11 induces apoptosis in meningioma cells. Congress of Neurological Surgeons Annual Meeting Boston, MA, November 1999 (abstract)
27. Macdonald DR, Cascino TL, Schold Jr, SC, Cairncross JG, Response criteria for Phase II studies of supratentorial malignant glioma J Clin Oncol 8(7):1277-1280, 1990
28. Stupp R, Dietrich PY, Kraljevic SO, Picca A, Maillard I, et al, Promising survival for patients treated with newly diagnosed glioblastoma multiforme treated with concurrent radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20: 1375-1382, 2002
29. Hvizdos KM, Goa KL, Temozolomide CNS Drugs 12(3): 237-243, 1999